Physician profile
Eva Agocs
NPI 1780610493
$6,721.58
in general payments reported to CMS, 2019-2025
29 companies · $591 in 2025
The $591 reported for 2025 was more than what 91% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,081 · 2020: $758 · 2021: $1,461 · 2022: $943 · 2023: $1,019 · 2024: $869 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,478.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $912.20 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Electromed, INC. | $829.94 | 2019-2025 | Smartvest |
| Janssen Pharmaceuticals, INC | $798.92 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $766.93 | 2019-2025 | |
| Pfizer INC. | $687.13 | 2019-2025 | |
| Abbvie INC. | $465.29 | 2021-2025 | Teflaro, Dalvance, Avycaz |
| Astrazeneca Pharmaceuticals LP | $418.92 | 2019-2023 | Farxiga, Fasenra |
| Merck Sharp & Dohme LLC | $311.52 | 2019-2024 | Dificid, Verquvo, Zerbaxa |
| Gilead Sciences, INC. | $171.64 | 2021-2023 | Veklury |
| Otsuka America Pharmaceutical, INC. | $157.27 | 2019 | |
| Novo Nordisk INC | $156.59 | 2019-2025 | Rybelsus, Ozempic |
| Allergan, INC. | $124.65 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.41 | 2022-2024 | Xifaxan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $105.07 | 2023-2025 | Lifevest |
| Lundbeck LLC | $96.81 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $91.67 | 2022-2024 | Nuzyra |
| Sunovion Pharmaceuticals INC. | $80.16 | 2019 | |
| Melinta Therapeutics, LLC | $65.32 | 2020-2021 | |
| Nabriva Therapeutics, Plc | $62.27 | 2021 | |
| Alexion Pharmaceuticals, INC. | $53.30 | 2021-2023 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $48.62 | 2019-2025 | Eliquis |
| Kestra Medical Technology Services, INC. | $42.57 | 2023-2025 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $39.17 | 2023 | Givlaari |
| Tactile Systems Technology INC | $32.40 | 2019 | |
| Medtronic, INC. | $22.97 | 2021 | |
| Shionogi INC | $21.45 | 2023 | Fetroja |
| Kci USA, INC. | $18.96 | 2019 | |
| Amgen INC. | $18.21 | 2019 | |
| Smith+Nephew, INC. | $16.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Agocs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.